Bank of New York Mellon
LENZ

Bank of New York Mellon’s LENZ Therapeutics LENZ Stock Holding History

Bank of New York Mellon’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
56,016
+6,219
+12% +$50.1K ﹤0.01% 3978
2026
Q1 		$456K Buy
49,797
+5,742
+13% +$80.7K ﹤0.01% 3654
2025
Q4 		$705K Sell
44,055
-767
-2% -$22.4K ﹤0.01% 3438
2025
Q3 		$2.09M Buy
44,822
+868
+2% +$31.9K ﹤0.01% 2788
2025
Q2 		$1.29M Buy
43,954
+15,260
+53% +$415K ﹤0.01% 2982
2025
Q1 		$738K Sell
28,694
-520
-2% -$12.8K ﹤0.01% 3236
2024
Q4 		$843K Sell
29,214
-428
-1% -$13K ﹤0.01% 3255
2024
Q3 		$704K Sell
29,642
-10,095
-25% -$224K ﹤0.01% 3329
2024
Q2 		$687K Buy
39,737
+28,556
+255% +$499K ﹤0.01% 3389
2024
Q1 		$250K Buy
11,181
+316
+3% +$6.57K ﹤0.01% 3860
2023
Q4 		$199K Sell
10,865
-442
-4% -$7.3K ﹤0.01% 3954
2023
Q3 		$196K Buy
11,307
+589
+5% +$10.2K ﹤0.01% 3963
2023
Q2 		$195K Buy
+10,718
New +$214K ﹤0.01% 3981
2022
Q2 		– Sell
-10,943
Closed -$391K – 4713
2022
Q1 		$391K Buy
10,943
+4,403
+67% +$275K ﹤0.01% 3856
2021
Q4 		$569K Buy
6,540
+912
+16% +$75.6K ﹤0.01% 3723
2021
Q3 		$646K Buy
+5,628
New +$833K ﹤0.01% 3657

Other funds holding LENZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's LENZ Position: Q2 2026 in Review

Bank of New York Mellon increased its LENZ Therapeutics (LENZ) stake by 12% in Q2 2026, buying an estimated $50.1K and bringing the position to 56,016 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #3978.

Bank of New York Mellon first reported a position in LENZ in Q3 2021 and has held it in 16 quarters since. The position peaked at $2.09M in Q3 2025. 63 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Bank of New York Mellon held 56,016 shares of LENZ Therapeutics worth $318K as of Q2 2026.
  • Bank of New York Mellon bought 6,219 LENZ Therapeutics shares in Q2 2026, an estimated $50.1K.
  • LENZ Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3978 holding.
  • Bank of New York Mellon first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Bank of New York Mellon's LENZ Therapeutics position peaked at $2.09M in Q3 2025.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.